Press Release

Ischemic Heart Disease (IHD) Drugs Market to Grow with a CAGR of 4.20% through 2030

Rising Prevalence of Cardiovascular Risk Factors is expected to drive the Global Ischemic Heart Disease (IHD) Drugs Market growth in the forecast period, 2026-2030.


According to TechSci Research report, “Ischemic Heart Disease (IHD) Drugs - Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Ischemic Heart Disease (IHD) Drugs Market stood at USD 5.98 Billion in 2024 and is anticipated to grow with a CAGR of 4.20% through 2030. The growing prevalence of cardiovascular risk factors is a key driver for the global Ischemic Heart Disease (IHD) drugs market. The rise in conditions like hypertension, diabetes, obesity, and sedentary lifestyles leads to a higher incidence of IHD, driving demand for effective treatments. These factors contribute to the narrowing and stiffening of arteries, which increases the likelihood of IHD. Additionally, high stress, poor dietary habits, and smoking further contribute to the growing burden, particularly in both developed and emerging economies.

As more people are affected by these risk factors, there is a greater need for both preventative measures and therapeutic drugs to manage IHD. Increased awareness and focus on cardiovascular health have prompted more individuals to seek treatment, further escalating demand for IHD medications. This growing market demand is driving innovation in drug development, presenting expanded opportunities for pharmaceutical companies. Additionally, as healthcare access improves in emerging markets, and with the rising prevalence of these risk factors, there is a significant growth opportunity in these regions. The combination of rising chronic disease rates and continued advances in drug development will drive the expansion of the IHD drugs market worldwide.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on " Global Ischemic Heart Disease (IHD) Drugs Market

 

Global Ischemic Heart Disease (IHD) Drugs Market is segmented into disease class, drug class, regional distribution, and company.

Based on Drug Class, Anti-Dyslipidemic Drugs emerged as the fastest growing segment in the global market for Ischemic Heart Disease (IHD) Drugs in 2024. Dyslipidemia, characterized by elevated LDL cholesterol and low HDL cholesterol, is a significant risk factor for ischemic heart disease (IHD). With the aging global population and rising lifestyle-related risk factors such as poor diet and inactivity, dyslipidemia is becoming more prevalent, increasing the demand for medications to manage cholesterol levels. Anti-dyslipidemic drugs, particularly statins, are well-established for lowering LDL cholesterol and preventing cardiovascular events like heart attacks and strokes, making them essential in IHD treatment and driving consistent market growth. Additionally, newer therapies such as PCSK9 inhibitors and ezetimibe are gaining traction, especially among statin-intolerant patients or those requiring more aggressive cholesterol reduction. These advancements are contributing to the rapid expansion of the anti-dyslipidemic drug market. Rising awareness about cardiovascular health and the importance of cholesterol management has led to more diagnoses and early interventions, which help prevent severe forms of IHD, further boosting demand for these drugs. As governments, healthcare organizations, and physicians increasingly focus on preventing cardiovascular diseases, the recognition of dyslipidemia as a key modifiable risk factor has further emphasized the need for anti-dyslipidemic treatments. Collectively, these factors position the anti-dyslipidemic drugs segment as the fastest-growing in the IHD drugs market, as both established and emerging treatments gain wider adoption.           

Based on Region, the Asia Pacific region is expected to be fastest growing region during the forecast period in global Ischemic Heart Disease (IHD) Drugs market. The growing prevalence of risk factors like hypertension, diabetes, obesity, and poor diet, especially in countries such as China and India, is leading to a higher incidence of ischemic heart disease (IHD). As these conditions become more common, the demand for effective treatments increases. In countries like Japan, China, and South Korea, significant demographic shifts and aging populations are driving the rising incidence of IHD, further boosting treatment demand. Additionally, rapid improvements in healthcare infrastructure and access to advanced medical technologies in nations like China and India are enhancing the diagnosis and management of IHD, supporting market growth. Governments and private organizations in the Asia-Pacific region are making substantial investments in healthcare, particularly in cardiovascular health programs, which promote the use of IHD treatments. Growing awareness of cardiovascular health and an increased focus on early detection and prevention are leading to more IHD diagnoses, driving demand for medications. As the region faces a rising burden of chronic diseases, including cardiovascular conditions, there is a greater emphasis on long-term management of IHD, fueling the need for continuous and effective treatments, such as statins, anti-anginal drugs, and newer therapies. These combined factors position the Asia-Pacific region as the fastest-growing market for IHD drugs, with continued growth expected as healthcare needs evolve.

 

Major companies operating in Global Ischemic Heart Disease (IHD) Drugs Market are:

  • Bayer AG
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Actelion Pharmaceuticals Ltd.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“The global Ischemic Heart Disease (IHD) drugs market is evolving as both treatment options and patient demographics shift. The increasing focus on cost-effective, long-term therapies is driving the development of combination drugs that address multiple risk factors simultaneously. As chronic diseases become more prevalent due to urbanization and lifestyle changes, the market is seeing greater demand for medications that offer not just symptomatic relief but also disease-modifying effects. The growing integration of digital health solutions and telemedicine is further transforming patient care, enhancing adherence to IHD treatments. With these trends, the IHD drug market is poised for sustained growth, especially as patient-centric solutions gain momentum across regions”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Ischemic Heart Disease (IHD) Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Class (Angina Pectoris, Myocardial Infarction), By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global Ischemic Heart Disease (IHD) Drugs Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Ischemic Heart Disease (IHD) Drugs Market.

 

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com